Dupilumab (blinded)
2020-0798
Phase 2 small_molecule completed
Quick answer
Dupilumab (blinded) for Eosinophilic Gastritis is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Eosinophilic Gastritis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed